



Effective Date 4/1/2023
 Next Review Date 4/1/2024

Drug Quantity Management – Per Days Somatostatin Analogs – Mycapssa

Table of Contents	Product Identifier(s)
-------------------	-----------------------

National Formulary Medical Necessity	1	131877
Conditions Not Covered.....	2	
Background.....	2	
References	2	
Revision History.....	2	

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Mycapssa® (octreotide delayed-release capsules)

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Mycapssa. If the Drug Quantity Management rule is not met for the requested at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 days
Mycapssa® (octreotide delayed-release capsules)	20 mg capsules (28 capsules per wallet)	56 capsules (2 wallets)	168 capsules (6 wallets)

Cigna covers quantities as medically necessary when the following criteria are met:

1. If the individual requires a dose of 60 mg per day, approve the requested quantity, not to exceed 84 capsules per 28 days at retail or 252 capsules per 84 days at home delivery.
2. If the individual requires a dose of 80 mg per day, approve the requested quantity, not to exceed 112 capsules per 28 days at retail or 336 capsules per 84 days at home delivery.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Mycapssa, a somatostatin analog, is indicated for long-term maintenance treatment in **acromegaly individuals who have responded to and tolerated treatment with octreotide or lanreotide.**¹

Dosing

The initial recommended dose of Mycapssa is 20 mg administered twice daily (BID).¹ The dose of Mycapssa is then titrated based on insulin-like growth factor 1 (IGF-1) levels and the individual's signs and symptoms of acromegaly. The dose can then be increased in increments of 20 mg daily. For doses of 60 mg daily, Mycapssa should be administered as 40 mg in the morning and 20 mg in the evening. For doses of 80 mg daily, administer Mycapssa as 40 mg BID. The maximum recommended dose of Mycapssa is 80 mg per day.

Availability

Mycapssa is supplied as 20 mg delayed release capsules in wallets containing 28 capsules each.¹

References

1. Mycapssa® delayed-release capsules [prescribing information]. Needham, MA: Chiasma; June 2020.

Revision History

Type of Revision	Summary of Changes	Approval Date
New Policy	--	01/18/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.